vTv Therapeutics Inc. ((VTVT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
vTv Therapeutics Inc. is conducting a Phase 3 clinical study titled ‘Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 26-Week Double-Blind, Randomized, Placebo-Controlled Phase 3 Study.’ The study aims to evaluate the efficacy of cadisegliatin, a glucokinase activator, as an adjunctive therapy to insulin in patients with Type 1 Diabetes Mellitus. This research is significant as it explores potential advancements in diabetes management, potentially improving patient outcomes.
The study tests cadisegliatin in two dosages: 800 mg once daily (QD) and 800 mg twice daily (BID), compared to a placebo group. Cadisegliatin is designed to enhance insulin therapy by activating glucokinase, which plays a role in glucose metabolism.
The study employs a randomized, triple-masked, placebo-controlled design with parallel assignment. Participants are randomly allocated to one of three groups, and both participants and investigators are blinded to the treatment assignments. The primary purpose of the study is treatment-focused, aiming to assess the therapeutic benefits of cadisegliatin.
The study began on March 13, 2024, with primary completion expected in 2025. The most recent update was submitted on July 15, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could influence market dynamics.
This clinical update could impact vTv Therapeutics’ stock performance positively if the results demonstrate significant benefits of cadisegliatin. Investors should monitor this study closely, as successful outcomes could enhance the company’s competitive position in the diabetes treatment market.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.